Opdivo (nivolumab) and Yervoy (ipilimumab)
Posted on: October 31, 2023 *Updated on: May 27, 2024The combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) offers a significant survival benefit for patients with unresectable mesothelioma compared to traditional chemotherapy.
- The combined treatment of Opdivo and Yervoy results in a median survival of 18 months for patients with unresectable mesothelioma.
- This represents a four-month improvement compared to the survival rate observed with chemotherapy.
- Nearly 50% (or half) of the patients receiving Opdivo and Yervoy survived for at least two years.
This data suggests that the combination of Opdivo and Yervoy might offer improved survival outcomes for patients with unresectable mesothelioma, outperforming standard chemotherapy in this context.
However, as always, the effectiveness of treatments can vary between individuals. It’s essential to consult with oncologists or medical professionals familiar with the latest research and individual patient profiles to get a clear understanding of the potential benefits and risks associated with any treatment.